Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | RORC | P51449 | 4/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23291785 | 0.88 | RORC (0.44) | HDAC1HDAC8HDAC6PDK2CYP11B2 | |
| SCHEMBL30334978 | 0.88 | RORC (0.44) | HDAC1HDAC8HDAC6PDK2CYP11B2 | |
| SCHEMBL27201496 | 0.85 | USP30 (0.42) | USP30HDAC1HDAC8HDAC6PDK2 | |
| SCHEMBL27201620 | 0.81 | MEN1 (0.38) | PDK2MEN1KMT2A | |
| SCHEMBL19458932 | 0.81 | RORC (0.52) | USP30RORCMEN1KMT2A | |
| SCHEMBL19462755 | 0.81 | RORC (0.52) | USP30RORCMEN1KMT2A | |
| SCHEMBL22300718 | 0.81 | USP30 (0.47) | USP30RORCMEN1KMT2A | |
| SCHEMBL30929772 | 0.80 | CYP11B2 (0.45) | USP30HDAC1HDAC8HDAC6PDK2 | |
| SCHEMBL3249164 | 0.77 | GPR119 (0.47) | HDAC1HDAC8HDAC6PDK2CYP11B2 | |
| SCHEMBL15156278 | 0.76 | RORC (0.45) | USP30HDAC1HDAC8HDAC6PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | USP30 99/4885HDAC1 716/4885HDAC8 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.